Communiqués Egetis Therapeutics AB

Actions

EGTX

SE0003815604

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
7,910 ^SEK	-1,12%		+0,25%	+48,13%

16/09	Transcript : Egetis Therapeutics AB Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:50 PM
14/09	Lannebo Hälsa och Ny Teknik progresse de 5,9 % en août - Bico parmi les gagnants du mois	FW

Communiqués

04/09	Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026	AQ
03/09	Egetis Therapeutics to Participate in Upcoming Investor Conferences in September	AQ
31/08	Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan	AQ
21/08	Egetis' Interim report Q2 2026	AQ
07/08	Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026	AQ
10/06	Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency	AQ
29/05	Change in the number of shares and votes in Egetis Therapeutics	AQ
19/05	Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026	AQ
13/05	Exercise of options under employee stock option program and notification of insider trading	AQ
07/05	Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026	AQ
05/05	Egetis Therapeutics : – Corporate Presentation May 2026 final	PU
05/05	Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.	AQ
03/05	Egetis Therapeutics : Interim ReportQ12026	PU
30/04	Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026	AQ
30/04	Change in the number of shares and votes in Egetis Therapeutics	AQ
24/04	Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026	AQ
21/04	Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)	AQ
21/04	Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)	AQ
14/04	Bulletin from Egetis Therapeutics’ Annual General Meeting 2026	AQ
09/04	Egetis Appoints Tiago Nunes as Chief Medical Officer	AQ
08/04	Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®	AQ
07/04	Egetis Therapeutics : – Corporate Presentation April 2026	PU
30/03	Egetis Therapeutics : – Corporate Presentation April 2026	PU
27/03	Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency	AQ
27/03	Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency	AQ